Updated:
My Bio
My Bio is a corporate investor based in Seoul, founded 2011; the Altss profile covers its classification, headquarters, registration, AUM band, and key...
My Bio
My Bio is a corporate investor with its headquarters in Seoul, South Korea. It focuses on investments in the Asia region.
General information
Firm type
Corporate Investor
Year founded
2011
AUM
Undisclosed
Location
Region
Asia
Country
South Korea
City
Seoul
Corporate office
Seoul, South Korea
Principals
Jingzhen (Ginger) Ding
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at My Bio?
Jingzhen (Ginger) Ding is the Founder and likely the primary decision-maker. Her background includes a Partner role at MyBio Capital, a healthcare-focused investment firm. No additional investment committee members are currently disclosed by the firm.
How is My Bio related to MyBioGate and MyBio Capital?
MyBioGate is an affiliated entity focused on healthcare investment analysis, effectively extending My Bio's research capabilities. MyBio Capital is the prior firm where Jingzhen (Ginger) Ding served as a Partner before founding My Bio in 2021, meaning there is a common founder but they are separate entities (per Altss research).
Does My Bio participate in fund commitments or only direct deals?
The firm's known posture centers on direct co-investments alongside business partners like K2VC rather than committing as a limited partner to external funds. Its model co-publishes market research with partners and co-invests directly in healthcare startups identified through that intelligence pipeline.
What investment stages does My Bio typically target?
My Bio focuses on early-stage healthcare companies, consistent with its co-investment model alongside venture capital partners. The exact check size range is not publicly disclosed, but its partnership with K2VC suggests a presence in early-stage biotech and digital health rounds in Asia.
Which geographies does My Bio target?
The firm is based in Seoul and its business partner network targets cross-border opportunities between Asia and Western markets. Co-published research with K2VC and Bin Yuan Capital focuses on translating Asian healthcare innovation for global investor audiences.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: